- Oops!Something went wrong.Please try again later.
A month has gone by since the last earnings report for Celldex Therapeutics (CLDX). Shares have lost about 3.9% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Celldex due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Celldex Q3 Loss Narrower Than Expected, Revenues Miss
Celldex incurred a loss of 75 cents per share in third-quarter 2019, narrower than the Zacks Consensus Estimate of a loss of 84 cents but wider than the year-ago loss of 66 cents.
Total revenues in the quarter declined 42% year over year to $0.5 million and missed the Zacks Consensus Estimate of $0.94 million. The year-over-year decline was due to a decrease in revenues from the collaboration agreement with Bristol-Myers and contract with the International AIDS Vaccine Initiative.
Research and development expenses were down 6.7% year over year to $11.1 million in the quarter mainly due to lower personnel costs, and a decline in clinical study and contract manufacturing-related expenses. General and administrative expenses were $3.4 million, down 8.1% year over year, mainly attributable to lower personnel and marketing expenses.
As of Sep 30, 2019, Celldex had cash, cash equivalents and marketable securities of $72.9 million compared with $81.3 million as of Jun 30, 2019.
The company believes that its cash position as of the end of September plus anticipated net proceeds from future sales of its common stock under the agreement with Cantor will be adequate to fund working capital requirements as well as planned operations through 2020.
How Have Estimates Been Moving Since Then?
Fresh estimates followed an upward path over the past two months.
At this time, Celldex has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Celldex has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celldex Therapeutics, Inc. (CLDX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research